<DOC>
	<DOCNO>NCT01880385</DOCNO>
	<brief_summary>Multi-center , non randomise , open label , non control pilot study . Evaluating treatment bevacizumab association pre-operative chemotherapy , follow surgery , adjuvant chemotherapy radiotherapy Patients inflammatory breast cancer .</brief_summary>
	<brief_title>Efficacy Safety Bevacizumab Neodjuvant Treatment Inflammatory Breast Cancer</brief_title>
	<detailed_description>Pilot study evaluate safety efficacy add Bevacizumab neoadjuvant chemotherapy patient present non metastatic inflammatory breast cancer ( IBC ) . Patients receive 4 cycle chemotherapy FEC100 associate Fluorouracil ( 500 mg/m2 ) , Epirubicin ( 100 mg/m2 ) , Cyclophosphamide ( 500 mg/m2 ) Bevacizumab 15 mg/kg every day 1 ecah 21 day cycle 4 cycle . Six week end neoadjuvant chemotherapy , patient undergo mastectomy 4 cycle Docetaxel ( 100 mg/m2 ) adjuvant chemotherapy +/-Trastuzumab 8 mg/kg first cycle 6mg/kg every 3 week 17 cycle tumor overexpress Human Epidermal Growth Factor Receptor 2 ( HER2 ) . The primary objective study evaluate safety efficacy , i.e . pathologic complete response ( pCR ) 4 cycle FEC100+Bevacizumab IBC</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>• Patients must sign write informed consent form prior study specific procedure , Women , 20 year old , Performance status &lt; 2 ( ECOG ) , Histologically confirm inflammatory breast cancer T4d N , hormonal Status known , metastases accord last TNM classification , adequate hematologic function : absolute neutrophil count ≥ 1 500/mm3 Platelets ≥ 100 000/mm3 Hemoglobin ≥ 9 g/dL adequate liver function : ASAT ALAT &lt; à 3 ULN Alkaline Phosphatase &lt; 5 ULN Total bilirubin &lt; 1,5 ULN , adequate kidney function : creatinine &lt; 1,5 x normal creatinine Clearance ≥ 50ml/min ( accord cockcroft Gault formula ) Urine Dipstick proteinuria &lt; 2+ patient proteinuria ≥ 2 + dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate ≤ 1 g protein 24 hour , adequate coagulation cardiac function : Prothrombin ratio ≥ 70 % , Prothrombin time ≤ 1,5 upper limit normal ( ULN ) within 7 day prior enrolment Left Ventricular ejection fraction ( LVEF ) ≥ 55 % Patients childbearing potential positive pregnancy test ( serum urine ) prior enrollment Patients either postmenopausal , surgically sterile , use `` effective contraception '' ( definition `` effective contraception '' base judgment investigator ) Patients pregnant breastfeed Patient consider socially psychological unable comply treatment require medial followup , Concurrent participation another clinical trial treatment anticancer agent protocol specify period Patients unwilling unable sign date Ethics Committee ( EC ) / Institutional Review Board ( IRB ) approve patient informed consent form Patients unwilling unable comply schedule visit , treatment plan , laboratory test , study procedure Non inflammatory breast cancer lymphatic skin permeation , Metastases , Bilateral breast cancer Distant metastases ( stage IV ) History another cancer adequately treat carcinoma situ cervix uterus , basal squamous cell skin cancer Prior anti tumor therapy ( surgery , radiotherapy , chemotherapy , hormonal treatment target therapy ) except treatment give carcinoma situ cervix uterus , basal squamous cell skin cancer History evidence inherit bleed diathesis coagulopathy , History thrombotic disorder within last 6 month prior enrollment ( i.e . cerebrovascular accident , transient ischemic attack , subarachnoid hemorrhage ) , Uncontrolled hypertension ( systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ) without antihypertensive medication ; patient high initial blood pressure eligible entry criterion meet initiation adjustment antihypertensive medication , Any follow within 6 month prior enrollment : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft surgery , clinically symptomatic uncontrolled cardiovascular disease , clinically significant cardiac arrhythmia ( grade 34 ) Severe rest dyspnea due complication oxygen dependency , Diabetic patient treat oral antidiabetic insulin underlie cardiopathy ultrasound , Any severe acute illness active uncontrolled infection would preclude safe administration study therapy time enrolment Other severe underlie medical condition , could impair ability participate study Major surgery , significant traumatic injury within 28 day prior study treatment start anticipation need major surgery study treatment , Minor surgery , include insertion indwelling catheter , within 24 hour prior first bevacizumab infusion , Nonhealing wound , active peptic ulcer bone fracture , History abdominal fistula , diagnose tracheaoesophageal fistula grade 4 non gastrointestinal fistula , gastrointestinal perforation intraabdominal abscess within 6 month enrolment ,</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>inflammatory breast cancer</keyword>
	<keyword>non metastatic</keyword>
	<keyword>Avastin</keyword>
</DOC>